JP7458399B2 - 抗クローディン抗体及びそれらの使用 - Google Patents

抗クローディン抗体及びそれらの使用 Download PDF

Info

Publication number
JP7458399B2
JP7458399B2 JP2021532180A JP2021532180A JP7458399B2 JP 7458399 B2 JP7458399 B2 JP 7458399B2 JP 2021532180 A JP2021532180 A JP 2021532180A JP 2021532180 A JP2021532180 A JP 2021532180A JP 7458399 B2 JP7458399 B2 JP 7458399B2
Authority
JP
Japan
Prior art keywords
antibody
seq
antibodies
cells
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021532180A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512132A5 (https=
JP2022512132A (ja
JPWO2020114480A5 (https=
Inventor
リ，ヨン
シャン，フェンリ
ファン，スー
ダイ，シンチュアン
リ，ショウ
リ，ホン
リン，ユアン
キー，シャリ
ジャン，ユエジン
リ，ジン
ワン，ビン
ヤン，ジェームズ
スー，ユンペン
ローザ ファンティン，ヴァレリア
Original Assignee
ゼットリップ ホールディング リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゼットリップ ホールディング リミテッド filed Critical ゼットリップ ホールディング リミテッド
Publication of JP2022512132A publication Critical patent/JP2022512132A/ja
Publication of JP2022512132A5 publication Critical patent/JP2022512132A5/ja
Publication of JPWO2020114480A5 publication Critical patent/JPWO2020114480A5/ja
Application granted granted Critical
Publication of JP7458399B2 publication Critical patent/JP7458399B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021532180A 2018-12-07 2019-12-06 抗クローディン抗体及びそれらの使用 Active JP7458399B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/119797 2018-12-07
CNPCT/CN2018/119797 2018-12-07
PCT/CN2019/123588 WO2020114480A1 (en) 2018-12-07 2019-12-06 Anti-claudin antibodies and uses thereof

Publications (4)

Publication Number Publication Date
JP2022512132A JP2022512132A (ja) 2022-02-02
JP2022512132A5 JP2022512132A5 (https=) 2022-12-13
JPWO2020114480A5 JPWO2020114480A5 (https=) 2022-12-13
JP7458399B2 true JP7458399B2 (ja) 2024-03-29

Family

ID=70975310

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021532180A Active JP7458399B2 (ja) 2018-12-07 2019-12-06 抗クローディン抗体及びそれらの使用

Country Status (12)

Country Link
US (1) US20210380680A1 (https=)
EP (1) EP3891183A4 (https=)
JP (1) JP7458399B2 (https=)
KR (1) KR20210100655A (https=)
CN (1) CN113423735B (https=)
AU (1) AU2019391204A1 (https=)
BR (1) BR112021011014A2 (https=)
CA (1) CA3122135A1 (https=)
IL (1) IL283754A (https=)
MX (1) MX2021006681A (https=)
SG (1) SG11202105885WA (https=)
WO (1) WO2020114480A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12297265B2 (en) 2018-12-28 2025-05-13 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody and use thereof
CA3128502A1 (en) 2019-02-01 2020-08-06 Novarock Biotherapeutics, Ltd. Anti-claudin 18 antibodies and methods of use thereof
CN115943162A (zh) * 2020-06-19 2023-04-07 信达生物制药(苏州)有限公司 抗Claudin18.2抗体以及其用途
CN113929780A (zh) * 2020-07-13 2022-01-14 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
KR20230079096A (ko) * 2020-09-30 2023-06-05 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항체-약물 접합체를 포함하는 약제학적 조성물 및 약제학적 조성물의 용도
US20240034784A1 (en) * 2020-09-30 2024-02-01 Nanjing GenScript Biotech Co., Ltd. Antibodies targeting human claudin 18.2 and uses thereof
CN115109154A (zh) * 2021-03-17 2022-09-27 三优生物医药(上海)有限公司 一种靶向cldn18.2的抗体或其抗原结合片段及其应用
CN115611983A (zh) * 2021-07-14 2023-01-17 三优生物医药(上海)有限公司 Cldn18.2结合分子及其用途
WO2023066267A1 (en) * 2021-10-19 2023-04-27 Biosion Inc. Antibodies binding cldn18.2 and uses thereof
CN114044822B (zh) * 2021-10-28 2023-06-27 杭州博茵生物技术有限公司 血清淀粉样蛋白a抗体的重链和轻链可变区、抗体及运用
CN118139888A (zh) * 2021-11-05 2024-06-04 正大天晴药业集团股份有限公司 抗cldn18.2抗体及其用途
CN114395040B (zh) * 2022-02-09 2023-12-15 东南大学附属中大医院 再生蛋白reg1a单克隆抗体及其应用
WO2023196882A1 (en) 2022-04-06 2023-10-12 Zai Lab (Us) Llc Claudin 18.2 immunohistochemistry assay and use thereof
CN117229398A (zh) * 2022-06-15 2023-12-15 中山康方生物医药有限公司 抗cldn18.2抗体、其药物组合物及用途
CA3261520A1 (en) * 2022-07-08 2024-01-11 Telix Targeting Technologies, Inc. ANTIBODIES, THEIR MANUFACTURING PROCESSES AND METHODS OF USE
WO2024131683A1 (zh) * 2022-12-19 2024-06-27 华润生物医药有限公司 结合cldn18.2的抗体和抗体药物偶联物及其用途
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009517354A (ja) 2005-11-24 2009-04-30 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのクローディン１８に対するモノクローナル抗体
JP2010528075A (ja) 2007-05-29 2010-08-19 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのクローディン１８に対するモノクローナル抗体
JP2015518838A (ja) 2012-05-23 2015-07-06 ガニメド ファーマシューティカルズ アーゲー がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法
JP2016517447A (ja) 2013-03-18 2016-06-16 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのクローディン１８．２に対する抗体を含む治療法
WO2018006882A1 (zh) 2016-07-08 2018-01-11 科济生物医药（上海）有限公司 抗密蛋白18a2的抗体及其应用
JP2018513146A (ja) 2015-04-15 2018-05-24 ガニメド ファーマシューティカルズ ゲーエムベーハー クローディン１８．２に対する抗体を含む薬物コンジュゲート

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004024617A1 (de) * 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2018054484A1 (en) * 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009517354A (ja) 2005-11-24 2009-04-30 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのクローディン１８に対するモノクローナル抗体
JP2010528075A (ja) 2007-05-29 2010-08-19 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのクローディン１８に対するモノクローナル抗体
JP2015518838A (ja) 2012-05-23 2015-07-06 ガニメド ファーマシューティカルズ アーゲー がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法
JP2016517447A (ja) 2013-03-18 2016-06-16 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのクローディン１８．２に対する抗体を含む治療法
JP2018513146A (ja) 2015-04-15 2018-05-24 ガニメド ファーマシューティカルズ ゲーエムベーハー クローディン１８．２に対する抗体を含む薬物コンジュゲート
WO2018006882A1 (zh) 2016-07-08 2018-01-11 科济生物医药（上海）有限公司 抗密蛋白18a2的抗体及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lazar, G. A. et al.，"Engineered antibody Fc variants with enhanced effector function"，Proc. Natl. Acad. Sci. U. S. A.，2006年，Vol. 103，pp. 4005-4010

Also Published As

Publication number Publication date
IL283754A (en) 2021-07-29
MX2021006681A (es) 2021-11-17
KR20210100655A (ko) 2021-08-17
SG11202105885WA (en) 2021-07-29
CN113423735A (zh) 2021-09-21
CN113423735B (zh) 2024-02-13
BR112021011014A2 (pt) 2021-08-31
CA3122135A1 (en) 2020-06-11
EP3891183A1 (en) 2021-10-13
WO2020114480A1 (en) 2020-06-11
JP2022512132A (ja) 2022-02-02
AU2019391204A1 (en) 2021-06-24
US20210380680A1 (en) 2021-12-09
EP3891183A4 (en) 2022-08-31

Similar Documents

Publication Publication Date Title
JP7458399B2 (ja) 抗クローディン抗体及びそれらの使用
CN116063505B (zh) 抗gal3抗体及其用途
JP7084569B2 (ja) Ｖｉｓｔａ及びその結合パートナーの相互作用を遮断することによる癌治療
RU2708075C2 (ru) Конъюгаты анти-ртк7 антитело-лекарственное средство
US12281166B2 (en) Methods of treating inflammatory diseases by blocking Galectin-3
JP7785284B2 (ja) Ｃｄ３８抗体とｉｃａｍ１抗体およびそれらの使用
CN115427449A (zh) 抗Gal3抗体和使用方法
JP7835441B2 (ja) Ｇａｌ３とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法
CN118524852A (zh) 治疗或抑制心血管疾病的方法
JP2019525727A (ja) 新規の抗ｔｎｆｒｓｆ２１抗体及び使用方法
KR20240072932A (ko) B7-h3에 특이적으로 결합하는 항체
RU2815926C2 (ru) Антитела против клаудина и их применение
TWI862564B (zh) 癌治療用醫藥
HK40059021A (en) Anti-claudin antibodies and uses thereof
HK40059021B (zh) 抗-紧密连接蛋白抗体及其用途
US20220281973A1 (en) Antibodies and blocking the interaction of vista and its binding partner
HK40092141A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
HK40090814A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
HK40004013A (en) Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240318

R150 Certificate of patent or registration of utility model

Ref document number: 7458399

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150